Comparative Pharmacology
Head-to-head clinical analysis: OTEZLA versus OTEZLA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OTEZLA versus OTEZLA XR.
OTEZLA vs OTEZLA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apremilast is a small molecule inhibitor of phosphodiesterase 4 (PDE4), which increases intracellular cyclic AMP (cAMP) levels. Elevated cAMP modulates inflammatory cytokine production, reducing TNF-α, IL-17, IL-23, and other pro-inflammatory mediators.
Phosphodiesterase 4 (PDE4) inhibitor; increases intracellular cAMP levels, reducing pro-inflammatory cytokine production and modulating immune response.
30 mg orally twice daily after an initial titration schedule: Days 1-2: 10 mg AM; Days 3-4: 10 mg AM, 10 mg PM; Days 5-6: 10 mg AM, 20 mg PM; Day 7 onward: 30 mg twice daily.
30 mg orally twice daily after an initial 5-day titration: 10 mg AM on day 1, 10 mg AM and 10 mg PM on day 2, 10 mg AM and 20 mg PM on day 3, 20 mg AM and 20 mg PM on day 4, and 30 mg AM and 30 mg PM on day 5 and thereafter.
None Documented
None Documented
Terminal elimination half-life of 6-9 hours (mean 7.6 h) in healthy subjects; supports twice-daily dosing
Terminal elimination half-life is 6-9 hours in healthy subjects; in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), half-life increases to 15-20 hours, necessitating dose reduction.
Renal (58% as unchanged drug and metabolites; 39% as unchanged drug in urine), fecal (33% as metabolites)
Renal 58% (primarily as inactive metabolites), fecal 39% (as unchanged drug and metabolites), biliary excretion contributes minimally. Total clearance is approximately 8.5 L/h.
Category C
Category C
Phosphodiesterase-4 (PDE4) Inhibitor
Phosphodiesterase-4 (PDE4) Inhibitor